Connection

Michael Zile to Middle Aged

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Middle Aged.
Michael Zile
Connection Strength
2.154
Middle Aged
  1. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. Clin Cardiol. 2020 Dec; 43(12):1501-1510.
    View in: PubMed
    Score: 0.050
  2. Baroreflex Activation Therapy in Patients With Heart?Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2020 07 07; 76(1):1-13.
    View in: PubMed
    Score: 0.050
  3. Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. Am J Cardiol. 2019 09 01; 124(5):756-762.
    View in: PubMed
    Score: 0.046
  4. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients?With HFrEF. J Am Coll Cardiol. 2019 02 26; 73(7):795-806.
    View in: PubMed
    Score: 0.045
  5. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 05; 11(5):e004446.
    View in: PubMed
    Score: 0.043
  6. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.
    View in: PubMed
    Score: 0.043
  7. Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. Physiol Rep. 2017 Nov; 5(20).
    View in: PubMed
    Score: 0.041
  8. Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course. J Palliat Med. 2017 10; 20(10):1068-1073.
    View in: PubMed
    Score: 0.040
  9. Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. Circ Heart Fail. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.039
  10. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.036
  11. Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. Circ Heart Fail. 2016 Jan; 9(1):e002543.
    View in: PubMed
    Score: 0.036
  12. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct; 17(10):1066-74.
    View in: PubMed
    Score: 0.035
  13. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015 Apr 07; 131(14):1247-59.
    View in: PubMed
    Score: 0.034
  14. Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail. 2013 May; 6(3):508-16.
    View in: PubMed
    Score: 0.030
  15. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 2011 Dec; 4(6):614-9.
    View in: PubMed
    Score: 0.027
  16. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.027
  17. Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology. J Card Fail. 2011 Apr; 17(4):282-91.
    View in: PubMed
    Score: 0.026
  18. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011 May; 4(3):246-56.
    View in: PubMed
    Score: 0.026
  19. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010 Mar 30; 121(12):1393-405.
    View in: PubMed
    Score: 0.024
  20. Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). J Heart Lung Transplant. 2010 Jan; 29(1):86-92.
    View in: PubMed
    Score: 0.024
  21. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008 Sep 30; 118(14):1433-41.
    View in: PubMed
    Score: 0.022
  22. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. J Card Fail. 2008 Dec; 14(10):816-23.
    View in: PubMed
    Score: 0.022
  23. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.020
  24. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
    View in: PubMed
    Score: 0.019
  25. Diastolic heart failure: definitions and terminology. Prog Cardiovasc Dis. 2005 Mar-Apr; 47(5):307-13.
    View in: PubMed
    Score: 0.017
  26. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004 May 06; 350(19):1953-9.
    View in: PubMed
    Score: 0.016
  27. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg. 2002 Apr; 123(4):707-14.
    View in: PubMed
    Score: 0.014
  28. Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF. PLoS One. 2022; 17(1):e0262479.
    View in: PubMed
    Score: 0.014
  29. Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes. Nat Commun. 2022 01 11; 13(1):203.
    View in: PubMed
    Score: 0.014
  30. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022 03; 24(3):497-509.
    View in: PubMed
    Score: 0.014
  31. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 08 03; 10(15):e019545.
    View in: PubMed
    Score: 0.013
  32. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug; 110(8):1334-1349.
    View in: PubMed
    Score: 0.013
  33. Incidence and Outcomes of Pneumonia in Patients With Heart?Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
    View in: PubMed
    Score: 0.013
  34. Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. J Am Coll Cardiol. 2001 Mar 15; 37(4):1080-4.
    View in: PubMed
    Score: 0.013
  35. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.
    View in: PubMed
    Score: 0.013
  36. Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. J Am Heart Assoc. 2021 03 16; 10(6):e018127.
    View in: PubMed
    Score: 0.013
  37. Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. Am Heart J. 2021 07; 237:45-53.
    View in: PubMed
    Score: 0.013
  38. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail. 2021 04; 8(2):1706-1710.
    View in: PubMed
    Score: 0.013
  39. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.013
  40. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. JAMA. 2020 10 20; 324(15):1522-1531.
    View in: PubMed
    Score: 0.013
  41. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 12; 22(12):2370-2379.
    View in: PubMed
    Score: 0.013
  42. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiol. 2020 04 01; 5(4):432-441.
    View in: PubMed
    Score: 0.012
  43. Covariate adjusted reanalysis of the I-Preserve trial. Clin Res Cardiol. 2020 Nov; 109(11):1358-1365.
    View in: PubMed
    Score: 0.012
  44. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 02; 13(2):e006541.
    View in: PubMed
    Score: 0.012
  45. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 04; 222:183-190.
    View in: PubMed
    Score: 0.012
  46. Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 12 10; 74(23):2858-2873.
    View in: PubMed
    Score: 0.012
  47. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 12; 12(12):e006539.
    View in: PubMed
    Score: 0.012
  48. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020 02 04; 141(5):338-351.
    View in: PubMed
    Score: 0.012
  49. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 02 04; 141(5):352-361.
    View in: PubMed
    Score: 0.012
  50. Randomized trial of partial versus complete chordal preservation methods of mitral valve replacement: A preliminary report. Circulation. 1999 Nov 09; 100(19 Suppl):II90-4.
    View in: PubMed
    Score: 0.012
  51. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.
    View in: PubMed
    Score: 0.012
  52. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
    View in: PubMed
    Score: 0.012
  53. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
    View in: PubMed
    Score: 0.012
  54. Age-Related Characteristics and Outcomes of Patients With Heart?Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 08 06; 74(5):601-612.
    View in: PubMed
    Score: 0.012
  55. Health-Related Quality of Life in Heart?Failure With Preserved Ejection?Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 10; 7(10):862-874.
    View in: PubMed
    Score: 0.012
  56. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 08; 21(8):974-984.
    View in: PubMed
    Score: 0.012
  57. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
    View in: PubMed
    Score: 0.011
  58. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2019 05; 7(5):418-427.
    View in: PubMed
    Score: 0.011
  59. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The?PARADIGM-HF?Trial. J Am Coll Cardiol. 2019 03 26; 73(11):1264-1272.
    View in: PubMed
    Score: 0.011
  60. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circ Heart Fail. 2019 03; 12(3):e005766.
    View in: PubMed
    Score: 0.011
  61. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019 03; 21(3):337-341.
    View in: PubMed
    Score: 0.011
  62. Income Inequality and Outcomes in Heart?Failure: A Global Between-Country Analysis. JACC Heart Fail. 2019 04; 7(4):336-346.
    View in: PubMed
    Score: 0.011
  63. Differential Impact of Heart Failure With?Reduced Ejection Fraction on?Men?and?Women. J Am Coll Cardiol. 2019 01 08; 73(1):29-40.
    View in: PubMed
    Score: 0.011
  64. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018 12 11; 138(24):2763-2773.
    View in: PubMed
    Score: 0.011
  65. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
    View in: PubMed
    Score: 0.011
  66. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.011
  67. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circ Heart Fail. 2018 10; 11(10):e005133.
    View in: PubMed
    Score: 0.011
  68. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 12; 20(12):1701-1709.
    View in: PubMed
    Score: 0.011
  69. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019 01; 21(1):23-36.
    View in: PubMed
    Score: 0.011
  70. Safety and Feasibility of a Nocturnal Heart Rate Elevation-Exploration of a Novel Treatment Concept. J Card Fail. 2019 01; 25(1):67-71.
    View in: PubMed
    Score: 0.011
  71. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018 07; 11(7):e004962.
    View in: PubMed
    Score: 0.011
  72. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 06 01; 3(6):498-505.
    View in: PubMed
    Score: 0.011
  73. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018 06; 6(6):489-498.
    View in: PubMed
    Score: 0.011
  74. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.
    View in: PubMed
    Score: 0.011
  75. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018 03; 15(3):e1002541.
    View in: PubMed
    Score: 0.011
  76. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
    View in: PubMed
    Score: 0.011
  77. Cardiac macrophages promote diastolic dysfunction. J Exp Med. 2018 02 05; 215(2):423-440.
    View in: PubMed
    Score: 0.010
  78. Type of Atrial Fibrillation and Outcomes in?Patients With Heart Failure and Reduced?Ejection?Fraction. J Am Coll Cardiol. 2017 Nov 14; 70(20):2490-2500.
    View in: PubMed
    Score: 0.010
  79. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.010
  80. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.010
  81. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.010
  82. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017 07 06; 377(1):41-51.
    View in: PubMed
    Score: 0.010
  83. Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates. Heart Vessels. 2017 Oct; 32(10):1202-1213.
    View in: PubMed
    Score: 0.010
  84. Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. Am Heart J. 1997 Jun; 133(6):648-55.
    View in: PubMed
    Score: 0.010
  85. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 05; 5(5):333-340.
    View in: PubMed
    Score: 0.010
  86. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J. 2017 Jun; 188:35-41.
    View in: PubMed
    Score: 0.010
  87. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017 Mar 07; 38(10):742-750.
    View in: PubMed
    Score: 0.010
  88. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? JACC Clin Electrophysiol. 2017 03; 3(3):291-298.
    View in: PubMed
    Score: 0.010
  89. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 01 01; 2(1):79-85.
    View in: PubMed
    Score: 0.010
  90. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.
    View in: PubMed
    Score: 0.010
  91. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017 01; 19(1):129-137.
    View in: PubMed
    Score: 0.010
  92. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. 2016 09 01; 1(6):666-72.
    View in: PubMed
    Score: 0.010
  93. Influence of Sacubitril/Valsartan (LCZ696)?on?30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016 07 19; 68(3):241-248.
    View in: PubMed
    Score: 0.009
  94. Efficacy of Sacubitril/Valsartan Relative to?a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 10; 4(10):816-822.
    View in: PubMed
    Score: 0.009
  95. Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. J Card Fail. 2016 Oct; 22(10):753-60.
    View in: PubMed
    Score: 0.009
  96. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016 Nov 01; 37(41):3167-3174.
    View in: PubMed
    Score: 0.009
  97. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016 Oct; 18(10):1228-1234.
    View in: PubMed
    Score: 0.009
  98. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 06; 9(6).
    View in: PubMed
    Score: 0.009
  99. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. Eur J Heart Fail. 2016 08; 18(8):1021-31.
    View in: PubMed
    Score: 0.009
  100. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 07; 133(23):2254-62.
    View in: PubMed
    Score: 0.009
  101. The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio. Int J Cardiol. 2016 Jul 15; 215:521-6.
    View in: PubMed
    Score: 0.009
  102. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Apr; 9(4):e002763.
    View in: PubMed
    Score: 0.009
  103. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.009
  104. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.009
  105. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016 Feb; 4(2):152-158.
    View in: PubMed
    Score: 0.009
  106. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. N Engl J Med. 2015 Dec 03; 373(23):2289-90.
    View in: PubMed
    Score: 0.009
  107. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10; 66(19):2059-2071.
    View in: PubMed
    Score: 0.009
  108. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. J Card Fail. 2016 Apr; 22(4):283-93.
    View in: PubMed
    Score: 0.009
  109. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep; 17(9):925-35.
    View in: PubMed
    Score: 0.009
  110. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 07; 36(38):2576-84.
    View in: PubMed
    Score: 0.009
  111. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul; 8(4):717-24.
    View in: PubMed
    Score: 0.009
  112. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 07; 36(30):1990-7.
    View in: PubMed
    Score: 0.009
  113. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015 Jun; 3(6):487-496.
    View in: PubMed
    Score: 0.009
  114. Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates. Hypertens Res. 2015 Aug; 38(8):551-9.
    View in: PubMed
    Score: 0.009
  115. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14; 36(7):434-9.
    View in: PubMed
    Score: 0.009
  116. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015 May; 17(5):510-7.
    View in: PubMed
    Score: 0.009
  117. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail. 2015 Feb; 17(2):169-76.
    View in: PubMed
    Score: 0.008
  118. Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST). Circ Heart Fail. 2015 Jan; 8(1):17-24.
    View in: PubMed
    Score: 0.008
  119. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation. 2015 Jan 06; 131(1):43-53.
    View in: PubMed
    Score: 0.008
  120. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11):993-1004.
    View in: PubMed
    Score: 0.008
  121. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 Oct; 16(10):1096-103.
    View in: PubMed
    Score: 0.008
  122. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014 Sep; 7(5):740-51.
    View in: PubMed
    Score: 0.008
  123. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging. 2014 Sep; 7(9):870-8.
    View in: PubMed
    Score: 0.008
  124. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014 Jul; 16(7):817-25.
    View in: PubMed
    Score: 0.008
  125. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail. 2014 Jul; 16(7):778-87.
    View in: PubMed
    Score: 0.008
  126. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 May; 16(5):535-42.
    View in: PubMed
    Score: 0.008
  127. Systolic and diastolic mechanics in stress cardiomyopathy. Circulation. 2014 Apr 22; 129(16):1659-67.
    View in: PubMed
    Score: 0.008
  128. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014 Feb 11; 63(5):447-56.
    View in: PubMed
    Score: 0.008
  129. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J. 2014 Jan; 35(1):42-7.
    View in: PubMed
    Score: 0.008
  130. Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens. 2013 Oct; 26(10):1234-41.
    View in: PubMed
    Score: 0.008
  131. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation. 1992 Dec; 86(6):1718-26.
    View in: PubMed
    Score: 0.007
  132. Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling. Circ Heart Fail. 2012 Nov; 5(6):803-11.
    View in: PubMed
    Score: 0.007
  133. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2013 Mar; 34(9):676-83.
    View in: PubMed
    Score: 0.007
  134. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20; 380(9851):1387-95.
    View in: PubMed
    Score: 0.007
  135. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 01; 5(5):571-8.
    View in: PubMed
    Score: 0.007
  136. In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol. 2012 Oct 15; 110(8):1150-5.
    View in: PubMed
    Score: 0.007
  137. Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012 Jun; 18(6):487-92.
    View in: PubMed
    Score: 0.007
  138. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf. 2012 Mar 01; 35(3):233-44.
    View in: PubMed
    Score: 0.007
  139. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens. 2011 Sep; 29(9):1829-36.
    View in: PubMed
    Score: 0.007
  140. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011 Sep; 4(5):569-77.
    View in: PubMed
    Score: 0.007
  141. Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. J Card Fail. 2011 May; 17(5):366-73.
    View in: PubMed
    Score: 0.007
  142. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011 May; 4(3):324-31.
    View in: PubMed
    Score: 0.006
  143. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010 Sep; 3(5):580-7.
    View in: PubMed
    Score: 0.006
  144. Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol. 2010 Jul; 134(1):23-30.
    View in: PubMed
    Score: 0.006
  145. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010 Feb; 16(2):128-34.
    View in: PubMed
    Score: 0.006
  146. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 04; 359(23):2456-67.
    View in: PubMed
    Score: 0.006
  147. Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation. 2008 Sep 16; 118(12):1241-9.
    View in: PubMed
    Score: 0.005
  148. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol. 2008 Jul 15; 102(2):203-6.
    View in: PubMed
    Score: 0.005
  149. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008 Mar 18; 51(11):1073-9.
    View in: PubMed
    Score: 0.005
  150. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J. 2008 Jan; 155(1):113.e1-8.
    View in: PubMed
    Score: 0.005
  151. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23; 369(9579):2079-87.
    View in: PubMed
    Score: 0.005
  152. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant. 2007 Feb; 26(2):145-51.
    View in: PubMed
    Score: 0.005
  153. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol. 2007 Feb 15; 99(4):460-4.
    View in: PubMed
    Score: 0.005
  154. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8.
    View in: PubMed
    Score: 0.005
  155. Myocardial mechanisms causing heart failure early after cardiac transplantation. Transplant Proc. 2006 Nov; 38(9):2999-3003.
    View in: PubMed
    Score: 0.005
  156. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006 Sep 05; 114(10):1020-7.
    View in: PubMed
    Score: 0.005
  157. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006 Aug 01; 114(5):397-403.
    View in: PubMed
    Score: 0.005
  158. Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol. 2006 Aug 01; 98(3):383-5.
    View in: PubMed
    Score: 0.005
  159. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006 Mar; 131(3):679-85.
    View in: PubMed
    Score: 0.005
  160. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis. 2005 Dec; 20(3):147-53.
    View in: PubMed
    Score: 0.005
  161. Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation. 2005 Nov 15; 112(20):3107-14.
    View in: PubMed
    Score: 0.004
  162. Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients. J Heart Lung Transplant. 2005 Nov; 24(11):1969-72.
    View in: PubMed
    Score: 0.004
  163. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005 Oct; 11(8):576-85.
    View in: PubMed
    Score: 0.004
  164. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation. 2005 May 10; 111(18):2306-12.
    View in: PubMed
    Score: 0.004
  165. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
    View in: PubMed
    Score: 0.004
  166. Chronic mitral regurgitation: predictive value of preoperative echocardiographic indexes of left ventricular function and wall stress. J Am Coll Cardiol. 1984 Feb; 3(2 Pt 1):235-42.
    View in: PubMed
    Score: 0.004
  167. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003 Oct; 9(5):354-63.
    View in: PubMed
    Score: 0.004
  168. beta-Adrenergic and endothelin receptor interaction in dilated human cardiomyopathic myocardium. J Card Fail. 2001 Jun; 7(2):129-37.
    View in: PubMed
    Score: 0.003
  169. Preliminary report on high thoracic epidural analgesia: relationship between its therapeutic effects and myocardial blood flow as assessed by stress thallium distribution. J Cardiothorac Vasc Anesth. 2000 Dec; 14(6):657-61.
    View in: PubMed
    Score: 0.003
  170. Left ventricular length-force-shortening relations before and after surgical correction of chronic mitral regurgitation. J Am Coll Cardiol. 1998 Jan; 31(1):180-5.
    View in: PubMed
    Score: 0.003
  171. Effect of catheter positioning on the variability of measured gradient in aortic stenosis. Cathet Cardiovasc Diagn. 1993 Dec; 30(4):287-92.
    View in: PubMed
    Score: 0.002
  172. Chronotropic incompetence: a common and progressive finding in pacemaker patients. Am Heart J. 1992 May; 123(5):1216-9.
    View in: PubMed
    Score: 0.002
  173. Dialysis-induced alterations in left ventricular filling: mechanisms and clinical significance. Am J Kidney Dis. 1991 Mar; 17(3):277-85.
    View in: PubMed
    Score: 0.002
  174. Hemodynamic correlates of left ventricular versus right ventricular radionuclide volumetric responses to vasodilator therapy in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol. 1987 May 01; 59(12):1131-7.
    View in: PubMed
    Score: 0.001
  175. Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1986 Nov 01; 58(10):1046-50.
    View in: PubMed
    Score: 0.001
  176. Comparison of left and right ventricular end-systolic pressure-volume relations in congestive heart failure. J Am Coll Cardiol. 1985 Jun; 5(6):1326-34.
    View in: PubMed
    Score: 0.001
  177. Vasodilator effect on right ventricular function in congestive heart failure and pulmonary hypertension: end-systolic pressure--volume relation. Am J Cardiol. 1984 Jul 01; 54(1):132-6.
    View in: PubMed
    Score: 0.001
  178. Immunologic tests of value in diagnosis. 1. Acute phase reactants and autoantibodies. Postgrad Med. 1981 Aug; 70(2):163-78.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.